Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment (2026)

Peer-Reviewed Study · Al-Zoubi RM; Farhan A; Hanbali B; Al-Zoubi SR; Khan A; Shkoor M; Bani-Yaseen AD; Al Zoubi MS; et al. · October 15, 2026

Al-Zoubi RM et al., 2026-10-15: 2026 review of antiparasitic drugs repurposed for oncology (ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole) summarising preclinical mechanisms including Wnt/beta-catenin, PI3K/Akt/mTOR, microtubule disruption and cancer stem cell targeting.

Ivermectin, a macrocyclic lactone, has shown potent activity against breast, ovarian, and colorectal cancer models through modulation of the P-glycoprotein drug efflux pump, activation of chloride ion channels, and inhibition of oncogenic signaling.

n/a (PubMed abstract)

Al-Zoubi RM et al., 2026-10-15: 2026 review of antiparasitic drugs repurposed for oncology (ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole) summarising preclinical mechanisms including Wnt/beta-catenin, PI3K/Akt/mTOR, microtubule disruption and cancer stem cell targeting. Study type: review.